Research progress of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma
ZHU Guorui
YANG Qinqing
ZHANG Zitong
ZHANG Hongjuan
GUAN Shikui
Abstract：Hepatocellular carcinoma(HCC)is one of the most common malignant tumors.Tyrosine kinase inhibitors have been used in the mainstream treatment of HCC for many years,but their therapeutic efficacy is limited and the prognosis of patients is very poor.In recent years,the rapid rise of immunotherapy has provided a new direction for tumor treatment.In particular,immune checkpoint inhibitors have shown excellent clinical effect in the treatment of various solid tumors,including HCC.This article reviews various immune checkpoint inhibitors related to HCC and their clinical practice and research progress,aiming to provide a relevant reference and theoretical basis for the immunotherapy of HCC.
Keywords：Hepatocellular carcinomaImmunotherapyImmune checkpointsImmune checkpoint inhibitorsProgrammed cell death protein 1Programmed cell death ligand 1Cytotoxic T-lymphocyte-associated antigen 4
Publication Date：2025-06-28
Online Publishing Date：2025-09-10(First online date of this platform, not the publication date of the document)
Pages：9( 440-448 )